10X Genomics Inc (Class A)
Slēgts
SektorsVeselības aprūpe
68.59 3.41
Pārskats
Akcijas cenas izmaiņa
24h
Min
68.27
Max
69.04
Ienākumi | -4.5M -18M |
|---|---|
Pārdošana | 193K 151M |
EPS | -0.14 |
Peļņas marža | -11.872 |
Darbinieki | 1,178 |
EBITDA | -18M -19M |
Nākamie ieņēmumi | 2026. g. 5. nov. |
|---|
Tirgus kapitalizācija | 2.2B 8.2B |
|---|---|
Iepriekšējā atvēršanas cena | 65.18 |
Iepriekšējā slēgšanas cena | 68.59 |
Ziņu noskaņojums
By Acuity
13%
87%
15 / 339 Rangs Healthcare
10X Genomics Inc (Class A) Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Saistītās ziņas
Salīdzinājums
Cenas izmaiņa
10X Genomics Inc (Class A) Prognoze
Noskaņojums
By Acuity
15 / 339 Rangs Veselības aprūpe
Ziņu noskaņojums
Ļoti spēcīga liecība "buļļu" tendencei
Volatilitāte
Zem vidējā
Ziņu apjoms (RCV)
Vidējais
Finanšu rādītāji
Pārdošanas un administrēšanas izmaksas
Darbības izmaksas
Peļņa pirms nodokļu nomaksas
Pārdošana
Pārdošanas maksa
Bruto peļņa no pārdošanas
Procentu izdevumi par parādu
EBITDA
Pamatdarbības peļņa
$
Par 10X Genomics Inc (Class A)
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.